1. Pink Sheet
  2. >>Legislation

Pharma Legislation: From Pricing To Patents

 
• By Brenda Sandburg

Our table details more than 30 pharma-related bills introduced in the US Congress this year that target drug pricing, generics, patents, market exclusivity, and FDA approval of opioids.

United States Capitol Building in Washington DC USA

Drug pricing remains a red-hot issue in Congress, as is clear from the more than 30-pharma-related bills introduced this term. As potential deal making heats up, legislators are seeking a variety of ways to curb drug costs, from setting limits on price increases to speeding approval of generics, allowing importation of lower-cost drugs, and altering market exclusivities. (See chart at end of story).

One measure would impose penalties for price gouging. The CURE (Combating Unreasonable Rises and Excessively) High Drug Prices Act, S....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 
• By Eliza Slawther

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

Senate Panel Approves US CDC Director Candidate Monarez With Measles Outbreak Growing

 
• By Cathy Kelly

The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.

US FDA Advisory Committee Supports Vaccine Safety, Scrutinizes AE Reporting Quality

 
• By Sue Sutter

The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.